Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Feb 16, 2010 (rev. 1)


Yuh-Geng Tsay, president of the specialty diagnostics group at Thermo Fisher Scientific since 2006, will retire in May, a company spokesperson told PCR Insider this week. A replacement has not yet been announced.

Prior to the merger of Thermo Electron and Fisher Scientific in 2006, Tsay was group president of immunodiagnostics for Apogent Technologies, part of Fisher Scientific. He was also founder and president of Diagnostic Reagents, which Apogent acquired in 1998. Prior to Diagnostic Reagents, Tsay founded Yellowstone Diagnostics, which became part of Adeza Biomedical in 1988. Tsay received a PhD in organic chemistry from the University of Rochester.

PrognosDx Health has appointed Daniel Hunt to serve as acting senior VP of corporate development.

Hunt formerly was general counsel of licensing, contracts management, and patent law at Genentech, and was director of legal affairs at Abgenix. He also has been chief corporate counsel at Roche Molecular Systems, where he was responsible for business development, transactional support, and managing Roche's PCR licensing program.

Agilent Technologies has appointed Robert Schueren as vice president and general manager of genomics.

Schueren formerly was global head of companion diagnostics, clinical biomarkers, and sample operations at Genentech/Roche.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.